Cardiovascular Drugs and Therapy

, Volume 25, Issue 1, pp 3–12 | Cite as

Blockade of the Renin-Angiotensin System Ameliorates Apelin Production in 3T3-L1 Adipocytes

  • Wei-Wen Hung
  • Tusty-Jiuan Hsieh
  • Tzu Lin
  • Pong-Chun Chou
  • Pi-Jung Hsiao
  • Kun-Der Lin
  • Shyi-Jang Shin
Article

Abstract

Purpose

Angiotensin II (Ang II), the physiologically-active product of the renin-angiotensin system (RAS), has recently been found to be an adipokine secreted by adipocytes. Although Ang II is known to exert its effects via angiotensin II receptor type 1 (AT1R) or type 2 (AT2R), the roles of the two receptors in the adipose tissue are unclear. Apelin, another adipokine, has been found able to restore glucose tolerance in obese and insulin-resistant mice. Because they are both involved in metabolic disorders, there may be an interaction between the two adipokines.

Methods

To observe the expression of RAS and apelin, 3T3-L1 adipocytes were harvested after 1, 2, 4, and 6 days of differentiation. The RAS blockers captopril (10−4 M), perindopril (10−3 M), losartan (10−4 M), or PD123319 (10−4 M) were added at day 2 of differentiation and harvested at day 4 and 6, when apelin expression was measured. Expressions of mRNAs were detected by real-time PCR. Production of Ang II and apelin was measured from culture media by ELISA. Cellular lipid droplets were detected by oil-red staining.

Results

Our study showed that the mRNA expressions of AGT, renin, ACE1, and AT2R were up-regulated while AT1R mRNA was down-regulated during adipogenesis. Apelin expression increased during adipogenesis, and this increase was further augmented by blocking RAS. RAS blockers also prevented excessive lipid accumulation and the generation of ROS (reactive oxygen species) in differentiating adipocytes.

Conclusions

Our study suggests that RAS blockers achieve their beneficial effects by their enhancement of adipocyte secretion of apelin.

Key words

Adipocyte Adipokine Angiotensinogen Angiotensin-converting enzyme inhibitor Angiotensin receptor blocker 

Notes

Acknowledgments

This work was supported by grants from the Kaohsiung Municipal Hsiao-Kang Hospital (KMHK-95-040; KMHK-97-016) and the Medical Research Fund of Kaohsiung Medical University (QM094009), Taiwan. We also thank SERVIER and MERCK for providing the perindopril and losartan used in this study.

References

  1. 1.
    Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Sorensen TI, Virtue S, Vidal-Puig A. Obesity as a clinical and public health problem: is there a need for a new definition based on lipotoxicity effects? Biochim Biophys Acta. 2010;1801:400–4.PubMedGoogle Scholar
  3. 3.
    Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444:847–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008;8:437–45.PubMedCrossRefGoogle Scholar
  6. 6.
    Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept. 2005;132:27–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224–36.PubMedCrossRefGoogle Scholar
  10. 10.
    Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem J. 1997;328:701–6.PubMedGoogle Scholar
  11. 11.
    Mogi M, Iwai M, Horiuchi M. Emerging concept of adipogenesis regulation by the renin-angiotensin system. Hypertension. 2006;48:1020–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res. 1994;35:1378–85.PubMedGoogle Scholar
  13. 13.
    Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology. 1997;138:1512–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Yvan-Charvet L, Massiera F, Lamande N, et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology. 2009;150:1421–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Kouyama R, Suganami T, Nishida J, et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology. 2005;146:3481–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Kurata A, Nishizawa H, Kihara S, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006;70:1717–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens. 2008;21:206–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Putt FA. Manual of histopathological staining methods. New York: Wiley; 1972.Google Scholar
  19. 19.
    Baehner RL, Boxer LA, Davis J. The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood. 1976;48:309–13.PubMedGoogle Scholar
  20. 20.
    Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology. 1987;121:1616–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Saye J, Lynch KR, Peach MJ. Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension. 1990;15:867–71.PubMedGoogle Scholar
  22. 22.
    Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord. 1999;23:336–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270–7.PubMedGoogle Scholar
  24. 24.
    Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes. Horm Metab Res. 2001;33:189–95.PubMedCrossRefGoogle Scholar
  25. 25.
    Mallow H, Trindl A, Loffler G. Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res. 2000;32:500–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes. 2005;54:991–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Fowler JD, Johnson ND, Haroldson TA, Brintnall JA, Herrera JE, Katz SA, et al. Regulated renin release from 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2009;296:E1383–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol. 1993;264:C1570–6.PubMedGoogle Scholar
  29. 29.
    Muñoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens. 2009;27:2409–20.PubMedCrossRefGoogle Scholar
  30. 30.
    Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens. 2007;20:431–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol. 2008;90:343–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Sunter D, Hewson AK, Dickson SL. Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett. 2003;353:1–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Lee DK, George SR, O’Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci. 2006;27:190–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Principe A, Melgar-Lesmes P, Fernandez-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology. 2008;48:1193–201.PubMedCrossRefGoogle Scholar
  35. 35.
    Yue P, Jin H, Aillaud-Manzanera M, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;298:E59–67.PubMedCrossRefGoogle Scholar
  36. 36.
    Higuchi K, Masaki T, Gotoh K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007;148:2690–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118:3343–54.PubMedGoogle Scholar
  38. 38.
    Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005;130:7–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Castan-Laurell I, Vitkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008;158:905–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116:289–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Brody R, Peleg E, Grossman E, Sharabi Y. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs. Am J Hypertens. 2009;22:1126–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Kiess W, Petzold S, Topfer M, et al. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab. 2008;22:135–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010:535918. Epub 2010 Aug 5.Google Scholar
  45. 45.
    Falcão-Pires I, Gonçalves N, Henriques-Coelho T, Moreira-Gonçalves D, Roncon-Albuquerque Jr R, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;296:H2007–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol. 2009;296:H1329–35.PubMedCrossRefGoogle Scholar
  47. 47.
    Wang B, Jenkins JR, Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab. 2005;288:E731–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Kang YS, Song HK, Lee MH, Ko GJ, Cha DR. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract. 2010;89:141–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee MH, Song HK, Ko GJ, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int. 2008;74:890–900.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Wei-Wen Hung
    • 1
    • 3
  • Tusty-Jiuan Hsieh
    • 2
  • Tzu Lin
    • 2
  • Pong-Chun Chou
    • 1
  • Pi-Jung Hsiao
    • 1
  • Kun-Der Lin
    • 1
  • Shyi-Jang Shin
    • 1
    • 2
    • 4
  1. 1.Division of Endocrinology and Metabolism, Department of Internal MedicineKaohsiung Medical University HospitalKaohsiungTaiwan
  2. 2.Department of Medical Genetics, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  3. 3.Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang HospitalKaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.KaohsiungTaiwan

Personalised recommendations